Tests INCB161734 in adults with advanced solid tumors carrying a KRAS G12D mutation
Tests INCB161734, alone or with other cancer drugs, in adults with advanced solid tumors.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Key facts
- Where
- Camperdown, Darlinghurst, Melbourne, and Nedlands, AustraliaSee the 5 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a solid tumor that has spread or grown locally and carries the KRAS G12D mutation.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Locally advanced or metastatic solid tumor. ECOG performance status of 0 or 1.
- Earlier treatment
- For some parts of the trial: the disease got worse on standard treatment, or the person cannot take or declined standard treatment, or no standard treatment exists. No earlier treatment with a KRAS G12D inhibitor.
- Biomarker or test result
- KRAS G12D mutation in the tumor.
Main reasons for not taking part
- Earlier treatment with any KRAS G12D inhibitor
- Another invasive cancer within 1 year before the first dose
- History of organ transplant, including allogeneic stem cell transplantation
- Serious uncontrolled medical condition
- ECG abnormality, or organs that do not work well enough
Read by machine on 12 November 2026.
Where in Australia
- Chris Obrien LifehouseCamperdown, AustraliaTaking people
- St Vincent's Hospital SydneyDarlinghurst, AustraliaTaking people
- Peter MacCallum Cancer CentreMelbourne, AustraliaTaking people
- The Alfred HospitalMelbourne, AustraliaTaking people
- Linear Clinical ResearchNedlands, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT06179160EU 2023-507091-47-00
- Record updated
- 22 July 2026
- Original description
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.Read full original descriptionShow less
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Inclusion: ≥18 years old; Locally advanced or metastatic solid tumor with KRAS G12D mutation; For Part 1a and Part 2 Combination Groups 1, 2, and 7: Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, declined available therapies that are known to confer clinical benefit, or no standard available treatment to improve the disease outcome; Cohort specific requirements aas defined in the protocol; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion: Prior treatment with any KRAS G12D inhibitor; Known additional invasive malignancy within 1 year of the first dose of study drug; History of organ transplant, including allogeneic stem cell transplantation; Significant, uncontrolled medical condition; History or presence of an ECG abnormality; Inadequate organ function; Other protocol-defined Inclusion/Exclusion Criteria may apply.